MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 105 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $1,067,000 | -21.7% | 860,224 | +94.5% | 0.00% | 0.0% |
Q1 2017 | $1,363,000 | +168.8% | 442,304 | +255.6% | 0.00% | +100.0% |
Q4 2016 | $507,000 | -95.9% | 124,378 | -93.6% | 0.00% | -95.2% |
Q3 2016 | $12,384,000 | +12.3% | 1,950,306 | -4.7% | 0.02% | -16.0% |
Q2 2016 | $11,031,000 | -1.5% | 2,046,523 | +44.4% | 0.02% | +4.2% |
Q4 2015 | $11,197,000 | +248.9% | 1,417,296 | +446.1% | 0.02% | +300.0% |
Q2 2015 | $3,209,000 | -69.7% | 259,507 | -70.9% | 0.01% | -70.0% |
Q1 2015 | $10,603,000 | -47.8% | 892,508 | -50.4% | 0.02% | -53.5% |
Q4 2014 | $20,316,000 | +16.2% | 1,797,848 | -9.7% | 0.04% | -2.3% |
Q3 2014 | $17,483,000 | +16.7% | 1,991,222 | -3.1% | 0.04% | +4.8% |
Q2 2014 | $14,985,000 | +865.5% | 2,055,592 | +567.6% | 0.04% | +950.0% |
Q1 2014 | $1,552,000 | +48.8% | 307,886 | +57.4% | 0.00% | +33.3% |
Q4 2013 | $1,043,000 | +44.9% | 195,646 | +3.0% | 0.00% | +50.0% |
Q3 2013 | $720,000 | +373.7% | 189,900 | +740.3% | 0.00% | – |
Q2 2013 | $152,000 | – | 22,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lagoda Investment Management, L.P. | 775,571 | $2,389,000 | 0.93% |
KEMPNER CAPITAL MANAGEMENT INC. | 148,985 | $459,000 | 0.31% |
Yakira Capital Management, Inc. | 248,420 | $765,000 | 0.27% |
GARRISON BRADFORD & ASSOCIATES INC | 87,700 | $270,000 | 0.24% |
Cannell & Co. | 1,212,478 | $3,734,000 | 0.13% |
LeJeune Puetz Investment Counsel LLC | 3,976 | $180,000 | 0.13% |
ALPINE WOODS CAPITAL INVESTORS, LLC | 726,000 | $2,236,000 | 0.12% |
Virtus ETF Advisers LLC | 198,735 | $612,000 | 0.11% |
STONERIDGE INVESTMENT PARTNERS LLC | 199,227 | $614,000 | 0.08% |
Birchview Capital, LP | 44,000 | $136,000 | 0.08% |